39503-63-4Relevant academic research and scientific papers
Mimicry of a β-Hairpin Turn by a Nonpeptidic Laterally Flexible Foldamer
Meisel, Joseph W.,Hu, Chunhua T.,Hamilton, Andrew D.
, p. 3879 - 3882 (2018)
The design and characterization of a proteomimetic foldamer that displays lateral flexibility endowed by intramolecular bifurcated hydrogen bonds is reported. The MAMBA scaffold, derived from meta-aminomethylbenzoic acid, adopts a serpentine conformation that mimics the side chain projection of all four residues in a β-hairpin turn.
Heterofunctionalized Cavitands by Macrocyclization of Sequence-Defined Foldamers
Meisel, Joseph W.,Hu, Chunhua T.,Hamilton, Andrew D.
supporting information, p. 7763 - 7767 (2019/10/11)
Macrocyclic hosts have long been the workhorses of molecular recognition. Despite the widespread use of container-shaped molecules as synthetic receptors, an efficient preparation of cavitands bearing multiple functional groups has not been realized. This Letter describes a new cavitand derived from a sequence-defined oligoamide foldamer scaffold. A solid-phase synthesis approach is reported, which enables the display of multiple chemically diverse functional groups on the cavitand rim.
Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization
Ren, Jing,Li, Jian,Wang, Yueqin,Chen, Wuyan,Shen, Aijun,Liu, Hongchun,Chen, Danqi,Cao, Danyan,Li, Yanlian,Zhang, Naixia,Xu, Yechun,Geng, Meiyu,He, Jianhua,Xiong, Bing,Shen, Jingkang
supporting information, p. 2525 - 2529 (2014/05/20)
Heat shock protein 90 (HSP90) is a molecular chaperone to fold and maintain the proper conformation of many signaling proteins, especially some oncogenic proteins and mutated unstable proteins. Inhibition of HSP90 was recognized as an effective approach to simultaneously suppress several aberrant signaling pathways, and therefore it was considered as a novel target for cancer therapy. Here, by integrating several techniques including the fragment-based drug discovery method, fragment merging, computer aided inhibitor optimization, and structure-based drug design, we were able to identify a series of HSP90 inhibitors. Among them, inhibitors 13, 32, 36 and 40 can inhibit HSP90 with IC50 about 20-40 nM, which is at least 200-fold more potent than initial fragments in the protein binding assay. These new HSP90 inhibitors not only explore interactions with an under-studied subpocket, also offer new chemotypes for the development of novel HSP90 inhibitors as anticancer drugs.
